CYP2D6

Материал из hpluswiki
Перейти к навигации Перейти к поиску

Cytochrome P450 2D6 (EC 1.14.14.-) (CYPIID6) (Cholesterol 25-hydroxylase) (Cytochrome P450-DB1) (Debrisoquine 4-hydroxylase) [CYP2DL1]

Publications[править]

Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations.


Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.


[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].


Analysis of the variability of the pharmacokinetics of multiple drugs in young adult and elderly subjects and its implications for acceptable daily exposures and cleaning validation limits.


Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.


Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.


Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.


Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.


Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.


Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.


Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.


Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance.


Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.


Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly.


Covariates of tramadol disposition in the first months of life.


A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.


Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.


Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women.


CYP450, genetics and Parkinson's disease: gene x environment interactions hold the key.


Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.


Bioequivalence revisited: influence of age and sex on CYP enzymes.


Clinical pharmacokinetics of drugs used to treat urge incontinence.


[Effect of factors on plasma haloperidol concentration/dose ratio].


Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.


Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?


Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.


The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.


Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.


CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.


Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.


In vivo age-related changes in hepatic drug-oxidizing capacity in humans.


A review of developmental aspects of cytochrome P450.


Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity.


Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci.


Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.


Delayed ontogenesis of CYP1A2 in the human liver.


CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians.


Serotonin 5-HT2A receptor binding in platelets from healthy subjects as studied by [3H]-lysergic acid diethylamide ([3H]-LSD): intra- and interindividual variability.


Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.